Loading clinical trials...
Loading clinical trials...
EXACT: Randomized Phase II Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Conditions
Interventions
XL092
Nivolumab
Locations
2
United States
Washington University School of Medicine
St Louis, Missouri, United States
Columbia University Irving Medical Center
New York, New York, United States
Start Date
March 13, 2026
Primary Completion Date
December 31, 2027
Completion Date
December 31, 2028
Last Updated
April 3, 2026
NCT05969860
NCT04693377
NCT06500455
NCT07123090
NCT06391099
NCT06349642
Lead Sponsor
Karie Runcie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions